Deregulated neddylation in liver fibrosis

Imanol Zubiete‐Franco, Pablo Fernández‐Tussy, Lucía Barbier‐Torres, Jorge Simon, David Fernández‐Ramos, Fernando Lopitz‐Otsoa, Virginia Gutiérrez‐de Juan, Sergio López de Davalillo, Antonio Martín Duce, Paula Iruzubieta, Daniel Taibo, Javier Crespo, Juan Caballeria, Erica Villa, Igor Aurrekoetxea, Patricia Aspichueta, Marta Varela‐Rey, Shelly C Lu, José M. Mato, Naiara Beraza, Teresa C. Delgado, María L Martínez‐Chantar – 7 November 2016 – Hepatic fibrosis is a global health problem currently without effective therapeutic approaches.

Long‐term clinical impact and cost‐effectiveness of obeticholic acid for the treatment of primary biliary cholangitis

Sumeyye Samur, Matthew Klebanoff, Reiner Banken, Daniel S. Pratt, Rick Chapman, Daniel A. Ollendorf, Anne M. Loos, Kathleen Corey, Chin Hur, Jagpreet Chhatwal – 7 November 2016 – Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease that mainly affects middle‐aged women. Obeticholic acid (OCA), which was recently approved by the Food and Drug Administration for PBC treatment, has demonstrated positive effects on biochemical markers of liver function.

Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model

Bo Zhu, Lan Wei, Nicholas Rotile, Helen Day, Tyson Rietz, Christian T. Farrar, Gregory Y. Lauwers, Kenneth K. Tanabe, Bruce Rosen, Bryan C. Fuchs, Peter Caravan – 7 November 2016 – Hepatic fibrosis is associated with an overproduction of matrix proteins and a pathological increase of liver stiffness. Noninvasive magnetic resonance (MR) quantification of matrix can be assessed with a collagen‐binding molecular MR probe and stiffness by MR elastography, complementary techniques. This study used both imaging techniques to more accurately stage hepatic fibrosis in a rat model.

A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation

Nicolas Golse, Petru Octav Bucur, Oriana Ciacio, Gabriella Pittau, Antonio Sa Cunha, René Adam, Denis Castaing, Teresa Antonini, Audrey Coilly, Didier Samuel, Daniel Cherqui, Eric Vibert – 7 November 2016 – Although sarcopenia is a common complication of cirrhosis, its diagnosis remains nonconsensual: computed tomography (CT) scan determinations vary and no cutoff values have been established in cirrhotic populations undergoing liver transplantation (LT). Our aim was to compare the accuracy of the most widely used measurement techniques and to establish useful cutoffs in the setting of LT.

Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy

Jennifer A. Flemming, W. Ray Kim, Carol L. Brosgart, Norah A. Terrault – 5 November 2016 – Direct‐acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hepatic function. We analyzed trends in liver transplant (LT) wait‐listing (WL) to explore potential impact of effective medical therapy on WL registration. This is a cohort study using the Scientific Registry of Transplant Recipients database from 2003 to 2015.

Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients

Daimin Xiang, Zhuo Cheng, Hui Liu, Xue Wang, Tao Han, Wen Sun, Xiaofeng Li, Wen Yang, Cheng Chen, Mingyang Xia, Na Liu, Shengyong Yin, Guangzhi Jin, Terence Lee, Liwei Dong, Heping Hu, Hongyang Wang, Jin Ding – 5 November 2016 – Src‐homology 2 domain–containing phosphatase 2 (Shp2) has been reported to play an important role in the maintenance and self‐renewal of embryonic and adult stem cells, but its role in cancer stem cells (CSCs) remains obscure. Herein, we observed high expression of Shp2 in both chemoresistant hepatocellular carcinomas (HCCs) and recurrent HCCs from patients.

Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment

Jung Hee Kim, Dong Hyun Sinn, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik – 5 November 2016 – The long‐term clinical impact of low‐level viremia (LLV; <2,000 IU/mL) is not well understood. As a result, it is unclear whether the development of LLV during entecavir monotherapy requires a change in therapy.

Loss of the transforming growth factor‐β effector β2‐Spectrin promotes genomic instability

Jian Chen, Vivek Shukla, Patrizia Farci, Jaclyn Andricovich, Wilma Jogunoori, Lawrence N. Kwong, Lior H. Katz, Kirti Shetty, Asif Rashid, Xiaoping Su, Jon White, Lei Li, Alan Yaoqi Wang, Boris Blechacz, Gottumukkala S. Raju, Marta Davila, Bao‐Ngoc Nguyen, John R. Stroehlein, Junjie Chen, Sang Soo Kim, Heather Levin, Keigo Machida, Hidekazu Tsukamoto, Peter Michaely, Alexandros Tzatsos, Bibhuti Mishra, Richard Amdur, Lopa Mishra – 5 November 2016 – Exposure to genotoxins such as ethanol‐derived acetaldehyde leads to DNA damage and liver injury and promotes the development of cancer.

Subscribe to